AIM ImmunoTech

AIM

Biotechnology · Healthcare

Exchange

New York Stock Exchange American

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

AIM ImmunoTech is a small biotechnology company focused on developing drugs to treat serious diseases, including certain cancers and viral infections. Its main product candidate is Ampligen (rintatolimod), a drug designed to boost the immune system. The company is working to get Ampligen approved as a treatment for conditions like ME/CFS (chronic fatigue syndrome) and has explored its use against various cancers and viruses.

AIM ImmunoTech makes very little revenue and operates at a significant loss, funding itself primarily through stock offerings and grants rather than product sales. The company is based in Ocala, Florida, and operates almost entirely in the United States. Its financial metrics reflect a pre-commercial stage business with deeply negative margins. The central risk is that Ampligen has faced a long and difficult path through clinical trials and regulatory review, and the company's survival depends heavily on securing FDA approval or finding a larger partner to fund further development.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+4.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+67.8% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

18.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$10M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

AIM ImmunoTech is growing revenue at 4% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

0.0%

Thin — 0.0% gross margin

Profit after running costs

Operating Margin

0.0%

Thin — 0.0% operating margin

Return on the money invested

ROCE

-93.8%

Weak — -93.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-21.5%

Shrinking sales (-21.5% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-7610.5%

Burning cash (-7610.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.04

Conservative — low debt load (0.04)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial